amox-clav

In a study where the investigators changed their reporting scheme from routinely reporting (listing) amoxicillin–clavulanate (amox–clav) in the susceptibility report to listing cephalexin, they reduced the prescription of amox–clav by 70%, with cephalexin use concomitantly increasing ninefold (McNulty et al., 2011).

2017, Christopher D. Doern, Carey-Ann D. Burnham, “Selective Reporting and Antimicrobial Stewardship”, in Kerry LaPlante, Cheston Cunha, Haley Morrill, Louis Rice, Eleftherios Mylonakis, editors, Antimicrobial Stewardship: Principles and Practice, Wallingford: CABI, →ISBN, page 113